UNSPSC 51172162: Bietamiverine dihydrochloride

This classification denotes an antispasmotic agent with the molecular formula C19H30N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XWH8UR3OX, chemically known as bietamiverine dihydrochloride, (+/-)-, but more generally known as bietamiverine dihydrochloride, which bears US NIH Compound Identifier 197773. European Medicines Agency schedules bietamiverine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05825MIG.

Most nations, for tariff purposes, schedule bietamiverine dihydrochloride under HS 29333999. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.CL.

UNSPSC 51172162 Bietamiverine dihydrochloride is a Commodity code nominally covering a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code do not reflect procurement of bietamiverine itself. Instead, the tagged opportunities span offender drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution agreements. The code shows minimal relevant recent activity; the single opportunity actually aligned with pharmaceutical procurement (the Minnesota Multistate Cooperative Purchasing Alliance generic and OTC products RFP) concerns broad-based generic sourcing and supply chain logistics rather than a named chemical entity.

The only geographically concentrated issuing body across recent records is Texas — the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription contracting, and Collin County (Texas) Community Supervision and Corrections Department posted an RFP in July 2026 for offender drug testing services (due July 23, 2026, with an estimated contract value of $600,000 over two years plus three optional one-year renewals). The Minnesota Multistate Cooperative Purchasing Alliance RFP, posted January 20, 2026 with proposals due March 26, 2026, sought generic pharmaceuticals and OTC products through three authorized wholesalers for distribution across participating state and local facilities including Oregon. The code's current tagging does not align cleanly with bietamiverine-specific procurement; business development activity should focus on the broader generic pharmaceutical and state pharmacy benefit management segments rather than expect targeted opportunities under this commodity code.